COPENHAGEN, Denmark, April 27, 2012 (GLOBE NEWSWIRE) -- GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN) announced today the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare (MHLW) for Arzerra(R) (ofatumumab) for the treatment of chronic lymphocytic leukemia (CLL).
